Drugs / V118E
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07168915 | Oct 2025 → Jul 2027 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V118E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168915 ↗ |
| Modality | Vaccine | “Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria.” NCT07168915 ↗ |
| Route | Intramuscular | “Participants receive intramuscular (IM) injection of V118E in a 2-dose regimen administered on Day 1 and Day 29.” NCT07168915 ↗ |